BioNxt Solutions Strengthens Intellectual Property and Capital Position

The biopharmaceutical firm BioNxt Solutions is advancing on two critical fronts this month: solidifying its European intellectual property rights and restructuring its balance sheet. A key milestone is approaching, with a major European patent set to become formally effective, potentially serving as a significant catalyst for the company.

European Patent Nears Formal Effectiveness

A significant development for BioNxt’s proprietary drug delivery platform has been confirmed by the European Patent Office (EPO). The office has decided to grant European Patent No. 4539857. This patent protects the company’s technology for a sublingual Cladribin “Oral Thin Film” (ODF), a dissolvable strip designed for rapid drug absorption through the mucous membrane in the mouth.

The timing of the patent’s formal activation is crucial. It will become effective upon its publication in the European Patent Bulletin on March 11, 2026 (Bulletin 26/11), following validation in individual countries. Once completed, this intellectual property protection will extend across up to 39 member states of the European Patent Convention. The patent term is secured at least until June 14, 2043, contingent on meeting standard formal requirements like fee payments and national validation procedures.

A Versatile Platform Technology

While BioNxt’s lead candidate, BNT23001, is intended for the treatment of Multiple Sclerosis, the scope of the newly granted patent is notably broader. The claims encompass the sublingual administration of Cladribin for treating additional autoimmune and neurodegenerative diseases.

The company has specifically identified Myasthenia Gravis as another autoimmune condition under investigation for its ODF platform, an application that falls squarely within the patent’s protected claims.

Global IP Strategy and Clinical Development Path

The European patent is part of a broader intellectual property strategy. BioNxt references a previously communicated, finally granted patent from the Eurasian Patent Organization (EAPO), which provides coverage in eight member states. Furthermore, in October 2025, the company initiated a Track-One prioritized examination process for its patent application in the United States. Nationalization activities are also ongoing in other key markets, including Canada.

Should investors sell immediately? Or is it worth buying Bionxt Solutions?

On the operational side, BioNxt is preparing a human bioequivalence study for BNT23001. Given that Cladribin is already an approved active pharmaceutical ingredient, the development pathway is designed to demonstrate comparable bioavailability to existing oral formulations, in line with regulatory standards.

Debt Settlement Alters Share Structure

Parallel to its patent progress, BioNxt recently reconfigured a substantial financial obligation. On February 26, 2026, the company issued 6,008,883 common shares at an ascribed price of US$0.45 per share to settle outstanding debt of CAD $2,704,000.

This liability originated from 8% convertible debentures issued on December 7, 2022, and consisted of CAD $2.6 million in principal plus CAD $104,000 in accrued interest.

As part of the arrangement, the facilitating agent, Canaccord Genuity, received 300,444 shares at a price of US$0.63 per share. All shares issued in this transaction are subject to a statutory hold period of four months and one day under Canadian securities law.

In market trading, the share price presents a mixed picture. The stock closed at €0.38 on Wednesday, trading approximately 15% below its 200-day moving average—a technical indicator suggesting the prevailing trend continues to face headwinds.

All eyes now turn to the calendar. The publication on March 11, 2026, will formally activate the European patent, transforming the EPO’s decision into a enforceable component of the company’s European intellectual property strategy.